JGC
KPTI icon

J. Goldman & Co’s Karyopharm Therapeutics KPTI Stock Holding History

J. Goldman & Co’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$660K Buy
+67,600
New +$586K 0.02% 513

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

J. Goldman & Co's KPTI Position: Q2 2026 in Review

J. Goldman & Co opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 67,500 shares worth $659K. The stake represents 0.02% of the portfolio and ranks #514 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in KPTI as recently as Q3 2023.

J. Goldman & Co first reported a position in KPTI in Q3 2019 and has held it in 13 quarters since. The position peaked at $14M in Q1 2021. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • J. Goldman & Co held 67,500 shares of Karyopharm Therapeutics worth $659K as of Q2 2026.
  • Karyopharm Therapeutics was a new J. Goldman & Co position in Q2 2026.
  • Karyopharm Therapeutics made up 0.02% of J. Goldman & Co's portfolio in Q2 2026, its #514 holding.
  • J. Goldman & Co first reported a position in Karyopharm Therapeutics in Q3 2019 and has held it in 13 quarters since.
  • J. Goldman & Co's Karyopharm Therapeutics position peaked at $14M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.